Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Increased glucose availability sensitizes pancreatic cancer to chemotherapy.
Vaziri-Gohar A, Hue JJ, Abbas A, Graor HJ, Hajihassani O, Zarei M, Titomihelakis G, Feczko J, Rathore M, Chelstowska S, Loftus AW, Wang R, Zarei M, Goudarzi M, Zhang R, Willard B, Zhang L, Kresak A, Willis JE, Wang GM, Tatsuoka C, Salvino JM, Bederman I, Brunengraber H, Lyssiotis CA, Brody JR, Winter JM. Vaziri-Gohar A, et al. Among authors: hajihassani o. Nat Commun. 2023 Jun 28;14(1):3823. doi: 10.1038/s41467-023-38921-8. Nat Commun. 2023. PMID: 37380658 Free PMC article.
Clinical development of IDH1 inhibitors for cancer therapy.
Zarei M, Hue JJ, Hajihassani O, Graor HJ, Katayama ES, Loftus AW, Bajor D, Rothermel LD, Vaziri-Gohar A, Winter JM. Zarei M, et al. Among authors: hajihassani o. Cancer Treat Rev. 2022 Feb;103:102334. doi: 10.1016/j.ctrv.2021.102334. Epub 2021 Dec 28. Cancer Treat Rev. 2022. PMID: 34974243 Review.
Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors.
Vaziri-Gohar A, Cassel J, Mohammed FS, Zarei M, Hue JJ, Hajihassani O, Graor HJ, Srikanth YVV, Karim SA, Abbas A, Prendergast E, Chen V, Katayama ES, Dukleska K, Khokhar I, Andren A, Zhang L, Wu C, Erokwu B, Flask CA, Zarei M, Wang R, Rothermel LD, Romani AMP, Bowers J, Getts R, Tatsuoka C, Morton JP, Bederman I, Brunengraber H, Lyssiotis CA, Salvino JM, Brody JR, Winter JM. Vaziri-Gohar A, et al. Among authors: hajihassani o. Nat Cancer. 2022 Jul;3(7):852-865. doi: 10.1038/s43018-022-00393-y. Epub 2022 Jun 9. Nat Cancer. 2022. PMID: 35681100 Free PMC article.
Wild-type IDH1 inhibition enhances chemotherapy response in melanoma.
Zarei M, Hajihassani O, Hue JJ, Graor HJ, Loftus AW, Rathore M, Vaziri-Gohar A, Asara JM, Winter JM, Rothermel LD. Zarei M, et al. Among authors: hajihassani o. J Exp Clin Cancer Res. 2022 Sep 24;41(1):283. doi: 10.1186/s13046-022-02489-w. J Exp Clin Cancer Res. 2022. PMID: 36153582 Free PMC article.
Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer.
Zarei M, Hajihassani O, Hue JJ, Graor HJ, Rothermel LD, Winter JM. Zarei M, et al. Among authors: hajihassani o. bioRxiv [Preprint]. 2023 Mar 29:2023.03.29.534596. doi: 10.1101/2023.03.29.534596. bioRxiv. 2023. PMID: 37034685 Free PMC article. Preprint.
IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression.
Hue JJ, Graor HJ, Zarei M, Katayama ES, Ji K, Hajihassani O, Loftus AW, Vaziri-Gohar A, Winter JM. Hue JJ, et al. Among authors: hajihassani o. Mol Cancer Ther. 2022 Dec 2;21(12):1810-1822. doi: 10.1158/1535-7163.MCT-22-0055. Mol Cancer Ther. 2022. PMID: 36190971
The promyelocytic leukemia protein isoform PML1 is an oncoprotein and a direct target of the antioxidant sulforaphane (SFN).
Alhazmi N, Pai CP, Albaqami A, Wang H, Zhao X, Chen M, Hu P, Guo S, Starost K, Hajihassani O, Miyagi M, Kao HY. Alhazmi N, et al. Among authors: hajihassani o. Biochim Biophys Acta Mol Cell Res. 2020 Aug;1867(8):118707. doi: 10.1016/j.bbamcr.2020.118707. Epub 2020 Mar 31. Biochim Biophys Acta Mol Cell Res. 2020. PMID: 32243901 Free article.